NCT03960073View on ClinicalTrials.gov

Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Renal Insufficiency, ChronicHeart Failure With Preserved Ejection Fraction
Interventions
DIETARY_SUPPLEMENT

MitoQ

4 week 20mg oral daily dose of Mito Q

DIETARY_SUPPLEMENT

Placebo

4 week oral daily dose of TTP placebo

Trial Locations (1)

23298-0256

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03960073 - Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction | Biotech Hunter | Biotech Hunter